The most common adverse effects in studies were fatigue, decreased appetite, nausea, and infections. Urinary tract infection was the most common severe adverse effect.
Atezolizumab
Tocilizumab
Ixekizumab
Caplacizumab
Satralizumab
Risankizumab
Bimekizumab
Benralizumab